Shadi Shahouri, MD
Rheumatology · Wichita, KSNPI 1568457950
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Boehringer Ingelheim at 46.6% of the total. Among rheumatology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 667 payments — averaging $45.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$14K
- Amgen$3K
- AbbVie$3K
- CSL Behring$2K
- Pfizer$2K
- Novartis$1K
- plus $5K from 27 others
Across 294 payments — averaging $2133.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$151K
- CSL Behring$146K
- Gilead$134K
- Eli Lilly$77K
- GSK$60K
- Novartis$35K
- plus $24K from 1 others
What the payments were for
- Speaking & faculty fees$13,93546%
- Travel & lodging$1,4435%
- Food & beverage$14,87749%
- Education$3661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 13 | $14,281 |
| Amgen(2 entities) | 103 | $3,015 |
| AbbVie | 141 | $2,517 |
| CSL Behring | 14 | $2,135 |
| Pfizer | 121 | $2,023 |
| Novartis | 56 | $1,209 |
| Johnson & Johnson | 51 | $855 |
| Janssen Scientific Affairs, LLC | 6 | $713 |
| GSK | 34 | $709 |
| Genentech USA, Inc. | 36 | $542 |
| UCB, Inc. | 17 | $535 |
| E.r. Squibb & Sons, L.L.C. | 11 | $411 |
| Lilly USA, LLC | 13 | $218 |
| AstraZeneca(2 entities) | 6 | $184 |
| Mallinckrodt Hospital Products Inc. | 3 | $167 |
| Aurinia Pharma U.S., Inc. | 2 | $166 |
| Gilead | 5 | $145 |
| Radius Health, Inc. | 7 | $112 |
| Genentech, Inc. | 1 | $111 |
| Sobi, Inc | 1 | $107 |
| ANI Pharmaceuticals, Inc. | 3 | $73 |
| Mallinckrodt Enterprises LLC | 3 | $62 |
| Sanofi | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| Zyla Life Sciences, Inc. | 3 | $41 |
| Hospira, Inc. | 2 | $33 |
| Bristol Myers Squibb | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Merck | 2 | $28 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Antares Pharma, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,621 in reported general payments places this provider in the 90th percentile of 49 rheumatology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 52 | $509,804 |
| Humira PenAdalimumab | 49 | $339,960 |
| Enbrel SureclickEtanercept | 41 | $308,788 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $217,933 |
| RinvoqUpadacitinib | 32 | $199,656 |
| Xeljanz XrTofacitinib Citrate | 11 | $98,890 |
| Enbrel MiniEtanercept | 12 | $88,271 |
| Actemra ActpenTocilizumab | 13 | $39,592 |
| Hydroxychloroquine Sulfate | 1,282 | $32,587 |
| BenlystaBelimumab | 21 | $28,744 |
| MethotrexateMethotrexate Sodium | 1,169 | $15,541 |
| Leflunomide | 284 | $11,444 |
| Sulfasalazine | 454 | $7,954 |
| SavellaMilnacipran Hcl | 11 | $5,451 |
| Celecoxib | 165 | $3,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $2,517 | $205,10743 claims |
| GSKBenlysta | $709 | $28,74421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 49 rheumatology providers in Kansas.
Other rheumatology in Wichita
- Timothy ShaverWichita$39K
- Melanie RohrWichita$5K
- Rawaa EbrahemWichita$3K
- Praveena GorantlaWichita$3K
- Brannon DonovanWichita$2K
- Preethi KurakulaWichita$402
- Ruth BuschWichita$327
- Steen MortensenWichita$153
- Teresa ReynoldsWichita$134
- Nadia GibsonWichita$112
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.